Natera Analysts Race to Raise Targets as Nasdaq-100 Addition Looms

Natera has spent the past two weeks receiving a wave of analyst upgrades, while a potential Nasdaq-100 inclusion adds a mechanical buying catalyst that most notes have yet to fully price in.

The analyst revision cycle has been unusually uniform. Every firm that moved on the stock between October 1 and October 19 raised its price target while keeping its rating unchanged. JP Morgan lifted to $460 from $360 on October 14. Morgan Stanley moved to $435 from $355 a day earlier. Canaccord went furthest on October 19, raising to $500 from $375. The collective direction is unambiguous: the Street believes the prior targets underestimated Natera's trajectory, and the mean consensus target of roughly $410 is already close to the current price of $405.92 after a 10% gain over the past month. With the stock sitting just above the consensus mean, the analysts who lifted to $460 to $500 are now the ones setting the tone for where incremental upside lives.

The bull case centres on Signatera's grip on the MRD monitoring market, where Natera claims more than 90% share in a segment the company and its followers value at above $15 billion. The framework assumes average selling prices climb from roughly $1,275 toward $1,450 to $1,500, gross margins expand past 70%, and pharma partnerships eventually yield data licensing revenues running into eight or nine figures. The bear case is narrower but pointed: the ASP path is not linear, reimbursement gains could stall, and the 2027 Signatera Genome readouts mean a large portion of the upside story is still unproven. EV/EBITDA at around 7,100 times trailing figures and a negative earnings yield reflect the degree to which the stock is valued on future years, not current ones. Factor scores show the stock ranks in the 59th percentile on forward EPS growth and the 48th on EPS momentum over the past month, leaving valuation doing a lot of the heavy lifting.

The index angle deserves direct attention. ORTEX puts the probability of Natera joining the Nasdaq-100 at 69% in the December 2026 Annual Review, with a rank date of November 30 and a trade date of December 18 if the inclusion is confirmed. The stock is already 7.8% above the price at which the index rule flips the call (that threshold sits at $374.14). Estimated buying from index trackers in that scenario runs to $5.1 billion, equivalent to roughly 8.6 days of normal trading volume. Among 14 comparable past additions, the median move from announcement to effective was plus 2.1%, with 79% of names moving in the expected direction, and trade-day volume ran at 4.5 times normal. Natera also shows up as a candidate for the CRSP US Mid and CRSP US Large indices in the December Quarterly Review, which ORTEX puts at 70% probability each. None of these are confirmed, and ORTEX's forecasts are probabilities, not announcements.

The positioning picture is calm rather than charged. Short interest is 4.6% of the free float, elevated enough to note but not at a level that dominates the thesis. The one-month change is more telling: short positions grew by roughly 23% in absolute share terms between late September and mid-October, a jump that coincides almost exactly with the stock clearing its old highs. Borrowing remains trivially cheap at 0.31%, and availability is extremely loose at over 8,600%, meaning there is no friction for shorts entering or covering. Options have shifted in the opposite direction to the new short positions: the put/call ratio has dropped to 0.87, almost two standard deviations below its 20-day average of 1.06, and the lowest reading of the past year. The combination of rising short interest and a falling PCR is an unusual divergence. Options traders are leaning into calls while shorts are rebuilding, a split that tends to become interesting around a catalyst.

That catalyst is two weeks away. Q3 results are due November 6. The last print, in August, produced a one-day gain of 17.3% and held most of that over the following five days. Insider activity is worth noting in passing: Director Sheena Jonathan sold roughly 1,300 shares across multiple transactions on October 16, all under a pre-arranged 10b5-1 plan at prices around $400 to $409, totalling about $520,000. Planned sales under 10b5-1 carry less interpretive weight than discretionary trades, and the net 90-day insider flow for the company overall runs to roughly minus $33.6 million in value, a figure more reflective of equity compensation mechanics than any single directional view.

Wikipedia attention for Natera is running at a z-score of 2.5 against its own prior 90 days, the highest retail-attention reading in that window. With earnings in 16 days, the Nasdaq-100 rank date on November 30, and analysts still marking up targets, the next few weeks resolve several of these threads at once. The number to watch most closely is not the earnings print itself but whether the stock closes above $374 on November 30, the date the Nasdaq-100 eligibility ranking is set.